English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background: Eravacycline (ERV) is a novel, fully-synthetic fl uorocycline antibiotic of the tetracycline class with in vitro activity against Gram-negative pathogens, including extendedspectrum β-lactamase and carbapenemase-producing Enterobacteriaceae (ENT) as well as multidrug-resistant strains of Acinetobacter baumannii. To further characterize its activity in vitro, ERV was tested against new reference panels made available by the FDA and CDC for the testing of new antibacterial agents. Methods: Using Clinical Laboratory Standards Institute methodology, minimal inhibitory concentration (MIC) values for antibiotics were determined for isolates in the FDA-CDC Antimicrobial Resistance Isolate Bank (AR Bank) panels: 1) ENT Carbapenem Breakpoint Panel (“Breakpoint”), 2) Gram Negative Carbapenemase Detection Panel (“Detection”) and 3) ENT Carbapenemase Diversity Panel (“Diversity”). The Breakpoint panel contained 31 ENT of which 7 were meropenem-resistant, including 5 blaKPC isolates. The Detection panel was comprised of 80 isolates total; a 52 ENT subset contained carbapenemase genes blaIMP (n=1), blaKPC (n=8), blaNDM (n=10), blaOXA (n=5), blaSME (n=2), blaVIM (n=3). The Diversity panel contained 53 ENT with carbapenemase genes blaIMI (n=2), blaIMP (n=1), blaKPC (n=18), blaNDM (n=20), blaOXA (n=5), blaSME (n=6), and blaVIM (n=2). There were 14 A. baumannii isolates across all panels, of which 4 isolates had blaNDM and 8 had blaOXA genes. Results: The ERV MIC50/90 values and ranges against the Breakpoint, Detection (ENT subset), Diversity panels and A. baumannii isolates are shown in the Table.

open forum infectious diseases

Eravacycline Is Active Against Carbapenem-Resistant Enterobacteriaceae and Acinetobacter baumannii Isolates in the FDA-CDC Antimicrobial Resistance Isolate Bank Panels